Unilever PLC Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Unilever PLC, dated December 15, 2025, discloses transactions by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. The filing covers transactions executed on December 10, 2025, involving the reinvestment of dividends on beneficially owned shares.
Key Financial Metrics
The filing does not contain corporate financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific share transactions by executives. The following transaction metrics were observed:
- Instrument: Unilever PLC ordinary 3 1/2 pence shares (ISIN: GB00BVZK7T90).
- Transaction Type: Dividend reinvestment (DRIP) during an open trading period.
- Transaction Prices: GBP 48.2368 per share and EUR 55.1553 per share.
- Exchanges: London Stock Exchange (XLON) and Amsterdam Stock Exchange (XAMS).
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document serves solely as a regulatory notification of insider share acquisitions via dividend reinvestment.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on business strategy, risks, contingencies, or unusual items.
Important Facts for Investors
- Executive Participation: Eight senior executives participated in dividend reinvestment plans on December 10, 2025, including the CFO (Srinivas Phatak), Chief Legal Officer (Maria Varsellona), and various Business Group Presidents.
- Transaction Nature: All reported transactions were automatic reinvestments of dividends, not open-market purchases or sales of existing holdings.
- Compliance: All transactions were executed during an open trading period, adhering to insider trading regulations.
- Share Price: The filing confirms the share price at the time of transaction was approximately GBP 48.24 and EUR 55.16.
- Scope Limitation: This filing contains no data regarding Unilever's overall financial health, earnings, or strategic direction for the period.